REmission in Membranous Nephropathy International Trial (REMIT)
Stopped The study was deemed unfeasible due to unforeseen financial limitations
Conditions
- Primary Membranous Nephropathy
Interventions
- DRUG: Obinutuzumab
- DRUG: Oral prednisolone and cyclophosphamide
Sponsor
The University of Queensland
Collaborators